mll

Menin-MLL inhibitor 20 is an irreversible inhibitor of the menin-MLL interaction, exhibiting antitumor activities.

Menin-MLL inhibitor 4 has antitumor activity.Menin-MLL inhibitor 4 is an inhibitor of Menin- MLL (mixed-lineage leukemia protein) interaction .

Menin-mll inhibitor 21 is a selective, oral and irreversible Menin inhibitor. Menin-MLL inhibitor 21 promotes selective proliferation of β cells and improvement of β cell function in human islet cultures in vitro. Menin-MLL inhibitor 21 enhances glycemic control in animal models of diabetes. Menin-MLL inhibitor 21 induced a dose-dependent increase in insulin secretion that was augmented by a GLP-1 receptor agonist (RA).

M‑89 is a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein−Protein Interaction (Kd = 1.4 nM; IC50 = 25nM). M-89 binds to menin with a Kd value of 1.4 nM and effectively engages cellular menin protein at low nanomolar concentrations. M-89 inhibits cell growth in the MV4;11 and MOLM-13 leukemia cell lines carrying MLL fusion with IC50 values of 25 and 55 nM, respectively, and demonstrates >100-fold selectivity over the HL-60 leukemia cell line lacking MLL fusion.

Menin-MLL inhibitor MI-2 (MI2) is a potent menin-MLL interaction inhibitor with IC50 of 446 nM.

Revumenib (SNDX-5613) is a potent and selective oral inhibitor of menin-KMT2A interaction with Ki of 0.149 nM and IC50 between 10 and 20 nM, which can be used in the study of acute leukemia with MLL gene rearrangement.

OICR-9429 is a potent antagonist of the interaction that WDR5 effect with peptide regions of MLL and Histone 3. It reduces the viability of acute myeloid leukemia cells in vitro.

VTP50469 is a highly selective and orally active small molecule inhibitor of the Menin-MLL protein-protein interaction with potent anti-leukemic activity with a Ki of 104 pM.

MIV-6R inhibits Menin-MLL interaction (IC50: 56 nM) and can be used to study leukemia.

M-89, a highly potent and specific inhibitor of the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction, exhibits a Kd of 1.4 nM for menin binding. This compound holds potential for treating MLL leukemia.

VTP50469 fumarate is a highly selective and orally active inhibitor of Menin-MLL interaction (Ki: 104 pM), and has potently anti-leukemia activity.

MI-538 is an interaction between menin and MLL fusion proteins inhibitor(IC50 of 21 nM).

MI-3 (Menin-MLL Inhibitor) (Menin-MLL Inhibitor) is an effective inhibitor of Menin-MLL interaction (IC50: 648 nM).

MI-2-2 is an inhibitor of bivalent protein-protein interaction between menin and MLL with an IC50 of 46 nM. MI-2-2 binds to menin with Kd of 22 nM.

SGC0946 is a highly effective and specific DOT1L methyltransferase inhibitor (IC50: 0.3 nM); selectively kill mixed lineage leukemia cells.

MI-3454 is an orally active, selective and potent inhibitor of Menin-MLL1 interaction that inhibits the proliferation and induces differentiation of acute leukemia cells with MLL1 translocation or NPM1 mutation.MI-3454 induces complete remission or regression of leukemia in a mouse model of leukemia with MLL1 rearrangement or NPM1 mutation through the down-regulation of key genes involved in leukemogenesis. complete remission or remission.

Ziftomenib (KO-539) is an inhibitor of menin-MLL interaction with antitumor activity, suitable for leukemia research.

Iptacopan hydrochloride hydrate is a highly potent and highly selective factor B inhibitor.

Bleximenib oxalate (Menin-MLL inhibitor 24 oxalate) is a selective and highly efficient menin-MLL inhibitor. It shows antiproliferative activity in acute lymphoblastic leukemia (ALL) cell lines and inhibits the binding of the menin-KMT2A complex to chromatin at the target gene promoter.

CCI 007 is a selective inhibitor of MLL-r, CALM-AF10 and SET-NUP214 leukemia with IC50 of 3.5 uM against MLL-r leukemia cell line PER-485

MI-463 is a potent and orally bioavailable inhibitor of the menin-mLL interaction (IC50: 15.3 nM).

MI-503 is an efficient and selective Menin-MLL inhibitor with an IC50 of 14.7 nM. In human MLL leukemia cell lines, MI-503 has a significant growth inhibition effect (GI = 250 nM-570 nM).

Menin-MLL inhibitor-25 (compound A6) is a potent inhibitor of the Menin-MLL interaction, with an IC50 of 0.38 µM. It exhibits antiproliferative activity, induces apoptosis and G0/G1 cell cycle arrest, and can reverse differentiation arrest.

Menin-MLL inhibitor 33 (compound 15-a) is a potent Menin-MLL inhibitor, with an IC50 value of 3.6 nM, and exhibits antiproliferative activity.